^
CANCER:

Cutaneous T-cell Lymphoma





Show legend
Group by Gene:
Include preclinical:

0
IL-2 stimulant
denileukin diftitox
1
Retinoid X receptor modulator
bexarotene oral
2
HDAC inhibitor
vorinostat
3
PD1 inhibitor
pembrolizumab
4
STAT3 protein degrader
KT-333
5
PD-L1 inhibitor
durvalumab
6
Topoisomerase II inhibitor, DNA synthesis inhibitor
gemcitabine + doxorubicin hydrochloride
7
CD70 inhibitor
ARGX-110
8
SIK3 inhibitor, PI3K inhibitor, PI3Kγ inhibitor, PI3Kδ inhibitor
RP6530
9
CD30-targeted antibody-drug conjugate, Microtubule inhibitor
brentuximab vedotin
TEQ102
10
JAK1 inhibitor, JAK2 inhibitor
ruxolitinib
11
TNFα inhibitor, PD-L1 inhibitor, IL-12 inhibitor, IL-6 inhibitor
durvalumab + lenalidomide
No biomarker
TNFRSF8 positive
TNFRSF8 expression
RPS6 underexpression
ICOS underexpression
PD-1 overexpression
CD70 expression
IL10-L
TNFA-L
CCL20-L
PD-L1 underexpression
IL2RA expression